Erin Wright
Stock Analyst at Morgan Stanley
(4.63)
# 108
Out of 4,814 analysts
221
Total ratings
65.62%
Success rate
13.54%
Average return
Main Sectors:
Stocks Rated by Erin Wright
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PETS PetMed Express | Maintains: Underweight | $3.5 → $3.2 | $3.15 | +1.59% | 12 | Apr 17, 2025 | |
| MCK McKesson | Maintains: Overweight | $642 → $745 | $682.49 | +9.16% | 6 | Apr 2, 2025 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $20 → $19 | $14.88 | +27.73% | 8 | Mar 6, 2025 | |
| ELAN Elanco Animal Health | Maintains: Equal-Weight | $14 → $13 | $8.48 | +53.30% | 11 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $243 → $238 | $146.84 | +62.08% | 7 | Feb 14, 2025 | |
| HUM Humana | Maintains: Equal-Weight | $301 → $285 | $245.91 | +15.90% | 3 | Feb 12, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $280 → $272 | $172.22 | +57.94% | 21 | Feb 6, 2025 | |
| CI The Cigna Group | Maintains: Overweight | $403 → $379 | $324.77 | +16.70% | 4 | Jan 31, 2025 | |
| CAH Cardinal Health | Maintains: Overweight | $136 → $142 | $131.37 | +8.09% | 9 | Jan 31, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $559 → $550 | $406.46 | +35.31% | 12 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $31 | $31.33 | +0.06% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $25 | $16.54 | +51.19% | 21 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $23 | $12.82 | +79.41% | 12 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $15.62 | +28.08% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $145 → $172 | $161.71 | +6.36% | 5 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $643 → $551 | $406.87 | +35.42% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $9 → $7 | $10.89 | -35.69% | 7 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $69 → $65 | $63.08 | +3.04% | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $65.17 | +53.44% | 4 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $587 | $425.33 | +38.01% | 3 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $300 | $212.22 | +41.36% | 4 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $42 | $14.95 | +180.94% | 5 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $282 → $288 | $184.96 | +55.71% | 6 | Jun 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $342 → $352 | $102.64 | +242.96% | 4 | May 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $44 | $1.79 | +2,364.99% | 2 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $178 → $181 | $288.99 | -37.37% | 8 | Mar 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $17 | $100.62 | -83.10% | 6 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $121 | $33.88 | +257.14% | 7 | Jan 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $556 → $580 | $421.85 | +37.49% | 4 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $14.47 | +141.88% | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $205 | $137.25 | +49.36% | 2 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $12 → $11 | $17.93 | -38.65% | 6 | May 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $157 | $141.38 | +11.05% | 1 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $19.31 | +96.79% | 1 | May 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $31 → $17 | $6.51 | +161.14% | 1 | Nov 20, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $308 | $458.33 | -32.80% | 1 | Oct 25, 2017 |
PetMed Express
Apr 17, 2025
Maintains: Underweight
Price Target: $3.5 → $3.2
Current: $3.15
Upside: +1.59%
McKesson
Apr 2, 2025
Maintains: Overweight
Price Target: $642 → $745
Current: $682.49
Upside: +9.16%
Envista Holdings
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $20 → $19
Current: $14.88
Upside: +27.73%
Elanco Animal Health
Feb 26, 2025
Maintains: Equal-Weight
Price Target: $14 → $13
Current: $8.48
Upside: +53.30%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $243 → $238
Current: $146.84
Upside: +62.08%
Humana
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $301 → $285
Current: $245.91
Upside: +15.90%
Align Technology
Feb 6, 2025
Maintains: Overweight
Price Target: $280 → $272
Current: $172.22
Upside: +57.94%
The Cigna Group
Jan 31, 2025
Maintains: Overweight
Price Target: $403 → $379
Current: $324.77
Upside: +16.70%
Cardinal Health
Jan 31, 2025
Maintains: Overweight
Price Target: $136 → $142
Current: $131.37
Upside: +8.09%
IDEXX Laboratories
Jan 29, 2025
Maintains: Overweight
Price Target: $559 → $550
Current: $406.46
Upside: +35.31%
Dec 17, 2024
Maintains: Equal-Weight
Price Target: $27 → $31
Current: $31.33
Upside: +0.06%
Dec 17, 2024
Maintains: Equal-Weight
Price Target: $20 → $25
Current: $16.54
Upside: +51.19%
Dec 17, 2024
Maintains: Overweight
Price Target: $30 → $23
Current: $12.82
Upside: +79.41%
Dec 17, 2024
Maintains: Overweight
Price Target: $19 → $20
Current: $15.62
Upside: +28.08%
Dec 17, 2024
Upgrades: Overweight
Price Target: $145 → $172
Current: $161.71
Upside: +6.36%
Oct 23, 2024
Maintains: Overweight
Price Target: $643 → $551
Current: $406.87
Upside: +35.42%
Oct 11, 2024
Maintains: Underweight
Price Target: $9 → $7
Current: $10.89
Upside: -35.69%
Nov 14, 2023
Maintains: Underweight
Price Target: $69 → $65
Current: $63.08
Upside: +3.04%
Nov 2, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $65.17
Upside: +53.44%
Jul 14, 2023
Reiterates: Overweight
Price Target: $587
Current: $425.33
Upside: +38.01%
Aug 22, 2022
Assumes: Overweight
Price Target: $300
Current: $212.22
Upside: +41.36%
Jul 30, 2021
Maintains: Outperform
Price Target: $39 → $42
Current: $14.95
Upside: +180.94%
Jun 18, 2021
Maintains: Outperform
Price Target: $282 → $288
Current: $184.96
Upside: +55.71%
May 28, 2021
Maintains: Neutral
Price Target: $342 → $352
Current: $102.64
Upside: +242.96%
May 11, 2021
Maintains: Outperform
Price Target: $42 → $44
Current: $1.79
Upside: +2,364.99%
Mar 17, 2021
Maintains: Outperform
Price Target: $178 → $181
Current: $288.99
Upside: -37.37%
Feb 26, 2021
Maintains: Neutral
Price Target: $14 → $17
Current: $100.62
Upside: -83.10%
Jan 13, 2021
Maintains: Outperform
Price Target: $104 → $121
Current: $33.88
Upside: +257.14%
Jan 12, 2021
Maintains: Outperform
Price Target: $556 → $580
Current: $421.85
Upside: +37.49%
Jan 5, 2021
Initiates: Neutral
Price Target: $35
Current: $14.47
Upside: +141.88%
Jul 23, 2020
Maintains: Outperform
Price Target: $181 → $205
Current: $137.25
Upside: +49.36%
May 5, 2020
Maintains: Neutral
Price Target: $12 → $11
Current: $17.93
Upside: -38.65%
Apr 2, 2020
Maintains: Outperform
Price Target: $175 → $157
Current: $141.38
Upside: +11.05%
May 9, 2018
Maintains: Outperform
Price Target: $42 → $38
Current: $19.31
Upside: +96.79%
Nov 20, 2017
Maintains: Underperform
Price Target: $31 → $17
Current: $6.51
Upside: +161.14%
Oct 25, 2017
Maintains: Neutral
Price Target: $300 → $308
Current: $458.33
Upside: -32.80%